148 related articles for article (PubMed ID: 28704327)
1. Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group.
Altman AD; Lambert P; Love AJ; Turner D; Lotocki R; Dean E; Popowich S; Nachtigal MW
Int J Gynecol Cancer; 2017 Oct; 27(8):1637-1644. PubMed ID: 28704327
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic status and epithelial ovarian cancer survival in Sweden.
Weiderpass E; Oh JK; Algeri S; Bellocco R
Cancer Causes Control; 2014 Aug; 25(8):1063-73. PubMed ID: 24906473
[TBL] [Abstract][Full Text] [Related]
3. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
Elstrand MB; Sandstad B; Oksefjell H; Davidson B; Tropé CG
Acta Obstet Gynecol Scand; 2012 Mar; 91(3):308-17. PubMed ID: 22050605
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
6. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.
Melamed A; Fink G; Wright AA; Keating NL; Gockley AA; Del Carmen MG; Schorge JO; Rauh-Hain JA
BMJ; 2018 Jan; 360():j5463. PubMed ID: 29298771
[TBL] [Abstract][Full Text] [Related]
7. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
Cowan RA; Tseng J; Ali N; Dearie H; Murthy V; Gennarelli RL; Iasonos A; Abu-Rustum NR; Chi DS; Long Roche KC; Brown CL
Gynecol Oncol; 2018 Apr; 149(1):43-48. PubMed ID: 29605049
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
[TBL] [Abstract][Full Text] [Related]
9. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
11. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Zhu J; Wang H; Liu CC; Lu Y; Tang H
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
Alexander VM; Gordon AN; Howard DH; Khanna N
Int J Gynecol Cancer; 2017 Sep; 27(7):1333-1342. PubMed ID: 28692633
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
14. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.
Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB
Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
16. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease.
Bristow RE; Chang J; Ziogas A; Randall LM; Anton-Culver H
Gynecol Oncol; 2014 Feb; 132(2):403-10. PubMed ID: 24361578
[TBL] [Abstract][Full Text] [Related]
17. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature.
Blake EA; Kodama M; Yunokawa M; Ross MS; Ueda Y; Grubbs BH; Matsuo K
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():97-105. PubMed ID: 25668134
[TBL] [Abstract][Full Text] [Related]
18. Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?
Dinkelspiel HE; Matrai C; Pauk S; Pierre-Louis A; Chiu YL; Gupta D; Caputo T; Ellenson LH; Holcomb K
Cancer Invest; 2016; 34(3):148-54. PubMed ID: 26986692
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for survival of epithelial ovarian cancer.
Linasmita V; Pattaraarchachai J; Daengdeelert P
Int J Gynaecol Obstet; 2004 Apr; 85(1):66-9. PubMed ID: 15050477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
